MPT0E028

Known as: HDAC Inhibitor MPT0E028, MPT 0E028, MPT-0E028 
An orally bioavailable N-hydroxyacrylamide-derived inhibitor of both human pan-histone deacetylase (HDAC) enzymes and the serine/threonine protein… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2014
01220122014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Histone deacetylase (HDAC) inhibitor has been a promising therapeutic option in cancer therapy due to its ability to induce… (More)
Is this relevant?
2014
2014
PURPOSE To investigate the antitumor activities of a histone deacetylase (HDAC) inhibitor, MPT0E028, plus sorafenib in liver… (More)
Is this relevant?
2014
2014
Purpose: To investigate the antitumor activities of a histone deacetylase (HDAC) inhibitor, MPT0E028, plus sorafenib in liver… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Epidermal growth factor receptor (EGFR), which promotes cell survival and division, is found at abnormally high levels on the… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Recently, histone deacetylase (HDAC) inhibitors have emerged as a promising class of drugs for treatment of cancers, especially… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?